Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Freiburgstr. 18, CH-3010, Bern, Switzerland.
Institute of Pathology, University of Bern, Bern, Switzerland.
Eur J Nucl Med Mol Imaging. 2022 Sep;49(11):3910-3916. doi: 10.1007/s00259-022-05745-5. Epub 2022 Apr 28.
Uncertain focal bone uptake (UBU) with intensive radiopharmaceutical avidity are frequently observed in patients undergoing [F]PSMA-1007 PET/CT for the detection of prostate cancer (PC). Such foci can pose diagnostic conundrums and risk incorrect staging. The aim of this short communication is to share the results of PET-guided biopsies of such foci.
A retrospective analysis revealed 10 patients who were referred to our department for PET-guided biopsy of UBU visible in a previous [F]PSMA-1007 PET/CT. [F]-PSMA-1007 PET-guided biopsy was conducted for 11 PSMA-avid bone foci in these 10 patients. The biopsy materials were analysed for tissue typing, and immunohistochemistry (IHC) was performed for prostate-specific-membrane-antigen (PSMA) expression. The scans were analysed by two experienced physicians in a consensus read for clinical characteristics and radiopharmaceutical uptake of foci.
One out of 11 (9.1%) of the foci biopsied was confirmed as bone metastasis of PC with intense PSMA-expression, while 10/11 (90.9%) foci were revealed to be unremarkable bone tissue without evidence of PSMA expression at IHC. Amongst all bone foci assessed by biopsy, eight were visually classified as being at high risk of malignancy in the PET/CT (SUVmean 12.0 ± 8.1; SUVmax 18.8 ± 13.1), three as equivocal (SUVmean 4.6 ± 2.1; SUVmax 7.2 ± 3.0) and zero as low risk. No UBU had any CT correlate.
This cohort biopsy revealed that a small but relevant number of UBU are true metastases. For those confirmed as benign, no PSMA expression at IHC was observed, suggesting a non-PSMA mediated cause for intensive [F]PSMA-1007 uptake of which the reason remains unclear. Readers must interpret such foci with caution in order to reduce the risk of erroneous staging and subsequent treatment. PET-guided biopsy, particularly in the absence of morphological changes in the CT, can be a useful method to clarify such foci.
在进行前列腺癌(PC)的 [F]PSMA-1007 PET/CT 检测时,经常会观察到具有放射性药物高摄取的局灶性骨摄取(UBU)。这些病灶可能会带来诊断上的难题,并存在分期错误的风险。本短篇通讯的目的是分享这些病灶的 PET 引导活检结果。
回顾性分析显示,有 10 名患者因之前的 [F]PSMA-1007 PET/CT 中可见 UBU 而被转介至我科进行 PET 引导下的活检。对这 10 名患者的 11 个 PSMA 阳性骨病灶进行了 [F]-PSMA-1007 PET 引导下的活检。对活检材料进行组织学分析,并进行前列腺特异性膜抗原(PSMA)表达的免疫组织化学(IHC)分析。由两位有经验的医生进行共识阅读,对扫描进行分析,以评估病灶的临床特征和放射性药物摄取情况。
在 11 个活检病灶中,有 1 个(9.1%)被证实为具有强烈 PSMA 表达的 PC 骨转移,而 10/11(90.9%)个病灶在 IHC 中显示为无明显异常的骨组织,没有 PSMA 表达。在所有经活检评估的骨病灶中,8 个在 PET/CT 中被视觉分类为恶性风险较高(SUVmean 12.0 ± 8.1;SUVmax 18.8 ± 13.1),3 个为可疑(SUVmean 4.6 ± 2.1;SUVmax 7.2 ± 3.0),0 个为低风险。没有 UBU 与 CT 有任何相关性。
本队列活检显示,有一小部分但数量可观的 UBU 是真正的转移灶。对于那些被证实为良性的病灶,在 IHC 中没有观察到 PSMA 表达,这表明其放射性药物摄取强烈可能不是由 PSMA 介导的,其原因尚不清楚。为了降低分期错误和随后治疗的风险,读者在解读这些病灶时必须谨慎。特别是在 CT 无形态变化的情况下,PET 引导活检可以是一种有用的方法来明确这些病灶。